InSilico Medicine Cayman TopCo revenue and financials

3696 · HKEX · HKD

$35.56Change from previous close: −5.98%Absolute change: −$2.26

Close · November 16, 2026

In the fiscal year ended December 2025, InSilico Medicine Cayman TopCo reported revenue of $56.24M (−34.48% year over year). The net loss was $352.32M.

Annual revenue · 2025: $56.24M
  1. $30.15M2022
  2. $51.18M2023
  3. $85.83M2024
  4. $56.24M2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
−34.48%
2025 vs 2024
Net margin
-626.5%
2024: -19.9%

How InSilico Medicine Cayman TopCo is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item2025202420232022
Total revenue56.285.851.230.1
Cost of revenue10.48.312.611.0
Gross profit45.877.638.619.1
Selling, general and administrative23.723.025.120.8
Research and development81.491.997.378.2
Operating income-60.0-37.3-83.7-80.1
EBIT-60.0-37.3-83.7-80.1
EBITDA-57.3-32.9-80.6-79.4
Interest expense0.20.10.10.1
Pre-tax income-352-16.9-212-222
Income tax0.10.20.10.0
Net income-352-17.1-212-222
Net income to common shareholders-352-17.1-212-222
Basic EPS-4.48-0.24-3.13-3.31
Diluted EPS-4.48-0.24-3.13-3.31
Average shares (basic)78.771.867.667.1
Average shares (diluted)78.771.867.667.1

Companies in the group: same industry, similar size